COVID-19 (COronaVIrus Disease 19) is an infectious disease also known as an acute respiratory syndrome caused by the SARS-CoV-2. Although in children and adolescents SARS-CoV-2 infection produces mostly mild or moderate symptoms, in a certain percentage of recovered young people a condition of malaise, defined as long-COVID-19, remains. To date, the risk factors for the development of long-COVID-19 are not completely elucidated. Neurotrophins such as NGF (Nerve Growth Factor) and BDNF (Brain-Derived Neurotrophic Factor) are known to regulate not only neuronal growth, survival and plasticity, but also to influence cardiovascular, immune, and endocrine systems in physiological and/or pathological conditions; to date only a few papers have discussed their potential role in COVID-19. In the present pilot study, we aimed to identify NGF and BDNF changes in the serum of a small cohort of male and female adolescents that contracted the infection during the second wave of the pandemic (between September and October 2020), notably in the absence of available vaccines. Blood withdrawal was carried out when the recruited adolescents tested negative for the SARS-CoV-2 ("post-infected COVID-19"), 30 to 35 days after the last molecular test. According to their COVID-19 related outcomes, the recruited individuals were divided into three groups: asymptomatics, acute symptomatics and symptomatics that over time developed long-COVID-19 symptoms ("future long-COVID-19"). As a control group, we analyzed the serum of age-matched healthy controls that did not contract the infection. Inflammatory biomarkers (TNF-α, TGF-β), MCP-1, IL-1α, IL-2, IL-6, IL-10, IL-12) were also analyzed with the free oxygen radicals' presence as an oxidative stress index. We showed that NGF serum content was lower in post-infected-COVID-19 individuals when compared to healthy controls; BDNF levels were found to be higher compared to healthy individuals only in post-infected-COVID-19 symptomatic and future long-COVID-19 girls, leaving the BDNF levels unchanged in asymptomatic individuals if compared to controls. Oxidative stress and inflammatory biomarkers were unchanged in male and female adolescents, except for TGF-β that, similarly to BDNF, was higher in post-infected-COVID-19 symptomatic and future long-COVID-19 girls. We predicted that NGF and/or BDNF could be used as early biomarkers of COVID-19 morbidity in adolescents.

Serum NGF and BDNF in Long-COVID-19 Adolescents: a pilot study / Petrella, Carla; Nenna, Raffaella; Petrarca, Laura; Tarani, Francesca; Paparella, Roberto; Mancino, Enrica; DI MATTIA, Greta; Conti, MARIA GIULIA; Matera, Luigi; Bonci, Enea; Ceci, FLAVIO MARIA; Ferraguti, Giampiero; Gabanella, Francesca; Barbato, Christian; Grazia Di Certo, Maria; Cavalcanti, Luca; Minni, Antonio; Midulla, Fabio; Tarani, Luigi; Fiore, Marco. - In: DIAGNOSTICS. - ISSN 2075-4418. - 12:5(2022). [10.3390/diagnostics12051162]

Serum NGF and BDNF in Long-COVID-19 Adolescents: a pilot study

Raffaella Nenna
Co-primo
;
Laura Petrarca;Roberto Paparella;Enrica Mancino;Greta Di Mattia;Maria Giulia Conti;Luigi Matera;Flavio Maria Ceci;Giampiero FERRAGUTI;Luca Cavalcanti;Antonio Minni;Fabio Midulla;LUIGI TARANI
Penultimo
;
2022

Abstract

COVID-19 (COronaVIrus Disease 19) is an infectious disease also known as an acute respiratory syndrome caused by the SARS-CoV-2. Although in children and adolescents SARS-CoV-2 infection produces mostly mild or moderate symptoms, in a certain percentage of recovered young people a condition of malaise, defined as long-COVID-19, remains. To date, the risk factors for the development of long-COVID-19 are not completely elucidated. Neurotrophins such as NGF (Nerve Growth Factor) and BDNF (Brain-Derived Neurotrophic Factor) are known to regulate not only neuronal growth, survival and plasticity, but also to influence cardiovascular, immune, and endocrine systems in physiological and/or pathological conditions; to date only a few papers have discussed their potential role in COVID-19. In the present pilot study, we aimed to identify NGF and BDNF changes in the serum of a small cohort of male and female adolescents that contracted the infection during the second wave of the pandemic (between September and October 2020), notably in the absence of available vaccines. Blood withdrawal was carried out when the recruited adolescents tested negative for the SARS-CoV-2 ("post-infected COVID-19"), 30 to 35 days after the last molecular test. According to their COVID-19 related outcomes, the recruited individuals were divided into three groups: asymptomatics, acute symptomatics and symptomatics that over time developed long-COVID-19 symptoms ("future long-COVID-19"). As a control group, we analyzed the serum of age-matched healthy controls that did not contract the infection. Inflammatory biomarkers (TNF-α, TGF-β), MCP-1, IL-1α, IL-2, IL-6, IL-10, IL-12) were also analyzed with the free oxygen radicals' presence as an oxidative stress index. We showed that NGF serum content was lower in post-infected-COVID-19 individuals when compared to healthy controls; BDNF levels were found to be higher compared to healthy individuals only in post-infected-COVID-19 symptomatic and future long-COVID-19 girls, leaving the BDNF levels unchanged in asymptomatic individuals if compared to controls. Oxidative stress and inflammatory biomarkers were unchanged in male and female adolescents, except for TGF-β that, similarly to BDNF, was higher in post-infected-COVID-19 symptomatic and future long-COVID-19 girls. We predicted that NGF and/or BDNF could be used as early biomarkers of COVID-19 morbidity in adolescents.
2022
neurotrophins; NGF; BDNF; adolescents; long-COVID-19; biomarkers; SARS-CoV-2
01 Pubblicazione su rivista::01i Case report
Serum NGF and BDNF in Long-COVID-19 Adolescents: a pilot study / Petrella, Carla; Nenna, Raffaella; Petrarca, Laura; Tarani, Francesca; Paparella, Roberto; Mancino, Enrica; DI MATTIA, Greta; Conti, MARIA GIULIA; Matera, Luigi; Bonci, Enea; Ceci, FLAVIO MARIA; Ferraguti, Giampiero; Gabanella, Francesca; Barbato, Christian; Grazia Di Certo, Maria; Cavalcanti, Luca; Minni, Antonio; Midulla, Fabio; Tarani, Luigi; Fiore, Marco. - In: DIAGNOSTICS. - ISSN 2075-4418. - 12:5(2022). [10.3390/diagnostics12051162]
File allegati a questo prodotto
File Dimensione Formato  
Petrella_Serum NGF_2022.pdf

accesso aperto

Note: https://www.mdpi.com/2075-4418/12/5/1162
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.44 MB
Formato Adobe PDF
1.44 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1644862
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 13
social impact